These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 15379663)

  • 21. Colloidal systems for tumor targeting.
    Storm G; Crommelin DJ
    Hybridoma; 1997 Feb; 16(1):119-25. PubMed ID: 9085138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice?
    Fathi S; Oyelere AK
    Future Med Chem; 2016 Nov; 8(17):2091-2112. PubMed ID: 27774793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape.
    Zylberberg C; Matosevic S
    Drug Deliv; 2016 Nov; 23(9):3319-3329. PubMed ID: 27145899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of novel liposomal drugs for cancer treatment: Advances and prospects.
    He K; Tang M
    Chem Biol Interact; 2018 Nov; 295():13-19. PubMed ID: 28919304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposomes as biocompatible and smart delivery systems - the current state.
    Dymek M; Sikora E
    Adv Colloid Interface Sci; 2022 Nov; 309():102757. PubMed ID: 36152374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane modification by negatively charged stearyl-polyoxyethylene derivatives for thermosensitive liposomes: reduced liposomal aggregation and avoidance of reticuloendothelial system uptake.
    Iga K; Ohkouchi K; Ogawa Y; Toguchi H
    J Drug Target; 1994; 2(3):259-67. PubMed ID: 7812694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs.
    Chen J; Lu WL; Gu W; Lu SS; Chen ZP; Cai BC; Yang XX
    Expert Opin Drug Deliv; 2014 Apr; 11(4):565-77. PubMed ID: 24490763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimuli-responsive Smart Liposomes in Cancer Targeting.
    Jain A; Jain SK
    Curr Drug Targets; 2018 Feb; 19(3):259-270. PubMed ID: 26853324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
    Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
    AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposomes: applications in medicine.
    Banerjee R
    J Biomater Appl; 2001 Jul; 16(1):3-21. PubMed ID: 11475357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomal drug delivery systems--clinical applications.
    Goyal P; Goyal K; Vijaya Kumar SG; Singh A; Katare OP; Mishra DN
    Acta Pharm; 2005 Mar; 55(1):1-25. PubMed ID: 15907221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes.
    Bender HR; Kane S; Zabel MD
    J Vis Exp; 2016 Jul; (113):. PubMed ID: 27501362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo trafficking of long-circulating liposomes in tumour-bearing mice determined by positron emission tomography.
    Oku N; Tokudome Y; Tsukada H; Kosugi T; Namba Y; Okada S
    Biopharm Drug Dispos; 1996 Jul; 17(5):435-41. PubMed ID: 8830978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.
    Penate Medina O; Haikola M; Tahtinen M; Simpura I; Kaukinen S; Valtanen H; Zhu Y; Kuosmanen S; Cao W; Reunanen J; Nurminen T; Saris PE; Smith-Jones P; Bradbury M; Larson S; Kairemo K
    J Drug Deliv; 2011; 2011():160515. PubMed ID: 21490745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomes: An Emerging Approach for the Treatment of Cancer.
    Mishra K; Jain AK
    Curr Pharm Des; 2021; 27(20):2398-2414. PubMed ID: 33823772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
    Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
    J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. pH-sensitive liposomes--principle and application in cancer therapy.
    Karanth H; Murthy RS
    J Pharm Pharmacol; 2007 Apr; 59(4):469-83. PubMed ID: 17430630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of temoporfin-loaded liposome formulations: correlation of liposome and temoporfin blood concentration.
    Decker C; Schubert H; May S; Fahr A
    J Control Release; 2013 Mar; 166(3):277-85. PubMed ID: 23313962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.